These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22103444)

  • 21. Ultrafast cell switching for recording cell surface transitions: new insights into epidermal growth factor receptor signalling.
    Chiang YY; West J
    Lab Chip; 2013 Mar; 13(6):1031-4. PubMed ID: 23385220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of Aromatic Side Chains in the Active Site of FKBP12.
    Weininger U; Modig K; Geitner AJ; Schmidpeter PA; Koch JR; Akke M
    Biochemistry; 2017 Jan; 56(1):334-343. PubMed ID: 27936610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Requirements for peptidyl-prolyl isomerization activity: a comprehensive mutational analysis of the substrate-binding cavity of FK506-binding protein 12.
    Ikura T; Ito N
    Protein Sci; 2007 Dec; 16(12):2618-25. PubMed ID: 18029417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR Inhibition by Curcumin in Cancer Cells: A Dual Mode of Action.
    Starok M; Preira P; Vayssade M; Haupt K; Salomé L; Rossi C
    Biomacromolecules; 2015 May; 16(5):1634-42. PubMed ID: 25893361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FKBP12 binds to acylated H-ras and promotes depalmitoylation.
    Ahearn IM; Tsai FD; Court H; Zhou M; Jennings BC; Ahmed M; Fehrenbacher N; Linder ME; Philips MR
    Mol Cell; 2011 Jan; 41(2):173-85. PubMed ID: 21255728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR.
    Toyama K; Kobayakawa T; Nomura W; Tamamura H
    Chem Pharm Bull (Tokyo); 2018; 66(11):1083-1089. PubMed ID: 30381661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A general approach for chemical labeling and rapid, spatially controlled protein inactivation.
    Marks KM; Braun PD; Nolan GP
    Proc Natl Acad Sci U S A; 2004 Jul; 101(27):9982-7. PubMed ID: 15218100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR.
    Sekiguchi M; Kobashigawa Y; Kawasaki M; Yokochi M; Kiso T; Suzumura K; Mori K; Teramura T; Inagaki F
    Protein Eng Des Sel; 2011 Nov; 24(11):811-7. PubMed ID: 21900305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.
    Hwang Y; Chumbalkar V; Latha K; Bogler O
    Mol Cancer Res; 2011 Sep; 9(9):1199-208. PubMed ID: 21775422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins.
    Dunyak BM; Nakamura RL; Frankel AD; Gestwicki JE
    ACS Chem Biol; 2015 Nov; 10(11):2441-7. PubMed ID: 26322864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanding the Chemogenetic Toolbox by Circular Permutation.
    Lee YT; He L; Zhou Y
    J Mol Biol; 2020 May; 432(10):3127-3136. PubMed ID: 32277990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting prolyl isomerase activity by hybrid organic-inorganic molecules containing rhodium(II) fragments.
    Coughlin JM; Kundu R; Cooper JC; Ball ZT
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5203-6. PubMed ID: 25442313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands.
    Wu YQ; Wilkinson DE; Limburg D; Li JH; Sauer H; Ross D; Liang S; Spicer D; Valentine H; Fuller M; Guo H; Howorth P; Soni R; Chen Y; Steiner JP; Hamilton GS
    J Med Chem; 2002 Aug; 45(16):3558-68. PubMed ID: 12139467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
    Olsen JV; Blagoev B; Gnad F; Macek B; Kumar C; Mortensen P; Mann M
    Cell; 2006 Nov; 127(3):635-48. PubMed ID: 17081983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMPing Up Healing Capacity with FKBP12 Ligand.
    Williams CH; Hong CC
    Cell Chem Biol; 2019 May; 26(5):619-620. PubMed ID: 31100260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stabilized Wittig olefination for bioconjugation.
    Lum KM; Xavier VJ; Ong MJ; Johannes CW; Chan KP
    Chem Commun (Camb); 2013 Dec; 49(95):11188-90. PubMed ID: 24150718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Break Away: FKBP12 sequestration as a target for increasing BMP activity.
    Taubert MC; Hausch F
    Cell Chem Biol; 2021 Sep; 28(9):1253-1255. PubMed ID: 34534467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mathematical model for peptide inhibitor design.
    Pang X; Zhou L; Zhang M; Xie F; Yu L; Zhang L; Xu L; Zhang X
    J Comput Biol; 2010 Aug; 17(8):1081-93. PubMed ID: 20726794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemical biology beyond binary codes.
    Michnick SW
    Chem Biol; 2000 Dec; 7(12):R217-21. PubMed ID: 11137822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ubiquitin-specific protease 22 promotes tumorigenesis and progression by an FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular carcinoma.
    Ye Q; Zhou W; Xu S; Que Q; Zhan Q; Zhang L; Zheng S; Ling S; Xu X
    MedComm (2020); 2023 Dec; 4(6):e439. PubMed ID: 38045832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.